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Background: Lithium-induced hyperparathyroidism (LIH) is a relative underrecognized complication of long-term
lithium treatment. Hypercalcemia may be the first, but often overlooked, sign of LIH. Symptoms of LIH can be
similar to the underlying psychiatric illness, which may cause a significant doctor’s delay in diagnosing LIH. The aim
of this study was to determine the prevalence of hypercalcemia in a cohort of psychiatric patients.
Methods: In this cross-sectional study, we collected data from 314 patients treated with lithium in an outpatient
clinic for bipolar disorder. Patients with bipolar disorder from the same clinics, who had never been treated with
lithium and of whom serum calcium levels were available, were included as controls (n = 15). Patient characteristics
and laboratory results were collected during the period of June 2010 till June 2011.
Results: The mean serum calcium level was 2.49 (SD 0.11) mmol/l. The point prevalence of hypercalcemia (>2.60
mmol/l) was 15.6%. In a comparable group of psychiatric patients not using lithium, the mean serum calcium level
was 2.37 mmol/l, and none of these patients had hypercalcemia (p = 0.001). The duration of lithium treatment was
the only significant predictor for the development of hypercalcemia (p = 0.002).
Discussion: The prevalence of hypercalcemia in lithium-treated patients was significantly higher than that in
non-lithium treated controls and correlated to the cumulative time lithium was used in this cross-sectional
study. We recommend that serum calcium levels should be routinely tested in patients using lithium for timely
detection of LIH or hypercalcemia due to other causes.
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Lithium is used effectively in the treatment of bipolar dis-
order over the last 60 years, and despite the availability of
many pharmacotherapeutic options, it remains the corner-
stone of long-term prophylaxis (Cade 1949). Hypercalce-
mia associated with lithium-induced hyperparathyroidism
(LIH) is a common, but easily overlooked, complication of
lithium treatment. Monitoring of serum calcium levels is
therefore recommended in the International Society for
Bipolar disorders (ISBD) consensus guidelines for the
safety monitoring of bipolar disorder treatments since
2009 (Ng et al. 2009). The first case of LIH was published
in 1973 (Garfinkel et al. 1973). The reported prevalence of* Correspondence: batwigt@gmail.com
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in any medium, provided the original work is phypercalcemia in patients on lithium therapy varies among
studies from 15% to 60% (Bendz et al. 1996; Ananth and
Dubin 1983; Davis et al. 1981; Järhult et al. 2010; Saunders
et al. 2009; Christensson 1976; Szalat et al. 2009;
Khandwala and Van Uum 2006).
Since symptoms of LIH such as fatigue, weakness, and
depression can be similar to the symptoms of the mood
disorder for which lithium therapy was initiated, this
may cause a significant doctor’s delay in the diagnosis of
LIH when misinterpreted (Khandwala and Van Uum
2006; Houweling et al. 2012; Rizwan and Perrier 2009).
The exact pathophysiology by which LIH develops is still
unknown. Lithium may induce LIH directly or only un-
mask or accelerate a previously unnoticed hyperparathyr-
oidism (Birnbaum et al. 1988; Tupin et al. 1968; Gerner
et al. 1977; Mellerup et al. 1976; Saxe and Gibson 1991;
Saxe et al. 1995). There are no clear predictors toOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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the way in which these patients should be treated is still a
matter of debate. Discontinuation of lithium treatment, if
possible, has been proven unsuccessful in most patients
that have been using lithium for longer periods (Garfinkel
et al. 1973; Bendz et al. 1996; Bendz et al. Järhult et al.
2010; Saunders et al. 2009; Houweling et al. 2012). Differ-
ent surgical approaches of parathyroidectomy have been
described, but calcimimetics or a ‘wait and see policy’ might
be an alternative to surgery (Bendz et al. 1996; Ananth and
Dubin 1983; Davis et al. 1981; Järhult et al. 2010;
Saunders et al. 2009; Christensson 1976; Szalat et al.
2009; Khandwala and Van Uum 2006; Houweling et al.
2012; Hundley et al. 2005; Sloand and Shelly 2006;
Gregoor and de Jong 2007).
Given the unfamiliarity with this condition, periodical
monitoring of serum calcium has only recently been
implemented in psychiatric guidelines and is still less
well-known in comparison to other well-known compli-
cations regarding thyroid and kidney function (Ng et al.
2009; Van de Beek et al. 2010). We therefore assume
that LIH is both underdiagnosed and undertreated.
The aim of this study was to determine the prevalence
of hypercalcemia in a large sample of outpatients treated
with lithium for bipolar disorder. To gain insight into
which of these patients are more prone to develop LIH,




The medical records of patients with bipolar disorder
who were treated with lithium between June 2010 and
June of 2011 at an outpatient clinic for bipolar disorder
were reviewed. Inclusion criterion was the continuous
use of lithium and at least one measurement of the
serum calcium level. Outpatients with bipolar disorder
from the same clinics, who had never been treated with
lithium and of whom serum calcium levels were avail-
able, were included as controls.
Outcomes
The following data were collected from the medical re-
cords: age, gender, past medical history, medication
current lithium dose, any possible interruptions during
the period that lithium was taken, and total cumulative
duration of lithium treatment. The following laboratory
variables were registered and analyzed by routine methods
(reference values between brackets): serum levels of lith-
ium (0.6 to 1.2 mmol/l), calcium (2.10 to 2.55 mmol/l),
parathormone (PTH) (1.0 to 7.0 pmol/l), albumin (38 to
42 mmol/l), creatinine (74 to 110 μmol/l), thyroid-
stimulating hormone (TSH) (0.35 to 5.00 mU/l), FT4 (9 to
27 pmol/l), sodium (135 to 145 mmol/l), and potassium(3.5 to 5.0 mmol/l). Also, any medication used by the pa-
tient was registered since thiazide/chloortalidon diuretics,
calcimimetics, vitamin D supplements, and calcium sup-
plements can induce increased serum calcium levels.
Data analysis
The Kolmogorov-Smirnov test was employed to test for
normal variance for each variable. Statistical differences
were calculated by means of the Student’s independent t
test and Pearson’s chi-square test. The missing data
resulted in a lower n than the actual number of patients.
Statistical significance was set as a two-tailed p < 0.05.
PASW Statistics IBM version 18 (IBM, New York, USA)
was used.
Definitions
The point prevalence of hypercalcemia was defined as
the prevalence of elevated serum calcium levels within
our cross-sectional 1-year time frame. If more than one
serum calcium level was available, the average serum
calcium level was determined.
The upper limit for serum calcium was set at 2.60
mmol/l. The total duration of lithium use was defined as
the cumulative period that lithium was taken by a pa-
tient expressed in months. If the use of lithium had been
interrupted, the total duration of lithium reflects the
sum of all individual periods.
Ethical committee
Approval was obtained from the medical ethics commit-




A total of 314 patients were identified who were cur-
rently using lithium and in which the serum calcium
level was determined at least once. The control group
consisted of 15 patients with bipolar disorder who had
never used lithium and from whom a serum calcium
measurement was available.
Patients on lithium
In the 314 lithium-treated patients, the mean age was 47
years and 61.5% were women (n = 195). The mean dos-
age of lithium was 960 (SD 280) mg a day. The mean
serum level of lithium was 0.74 (SD 0.19) mmol/l. The
mean period that lithium was taken was 117.6 (SD 91.2)
months, and the point prevalence of hypercalcemia was
15.6% (n = 49). None of these patients had a medical
history of hyperparathyroidism, hypercalcemia, or kidney
failure, nor did they use any medication with hypercalce-
mia as a possible side effect.
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was 2.37 (SD 0.10) mmol/l, which was significantly
(<0.001) lower compared to that of the lithium users
(Table 1). None of these patients had a serum calcium
level above 2.60 (mmol/l), as illustrated in Figure 1.
Subgroup analysis
Subgroup analysis showed that the cumulative duration
of lithium use (i.e., the total time that a patient had used
lithium regardless of any possible interruptions) was the
only predictor for the development of hypercalcemia.
The mean cumulative duration of lithium use was 165
months in hypercalcemic patients versus 109 months in
patients with normal calcium levels (p = 0.002).
In addition, we calculated a hypothetical lifetime lithium
dose by multiplying the cumulative duration of lithium
use with the most recent dose. This was significantly dif-
ferent between both groups (p = 0.002). All other fac-
tors such as gender (p = 0.457), current lithium dose
(p = 0.759), serum lithium level (p = 0.379), age (p = 0.174),
serum creatinine (p = 0.091), and thyroid function
(p = 0.176) did not differ significantly (Table 2).
Hypercalcemic patients
Of the 49 patients with calcium levels above 2.60 mmol/l,
3 patients were referred to an endocrine physician or sur-
geon to reveal the cause of hypercalcemia. Two of these
patients with serum calcium levels of 2.71 and 2.65 mmol/l
and elevated PTH levels of 17.2 and 53.6 pmol/l, respect-
ively (reference value 1.3 to 9.3 pmol/l), underwent minim-
ally invasive parathyroidectomy after preoperative work-up
confirmed the diagnosis of LIH. The third patient was
treated with cinacalcet since the preoperative work-up
showed inconsistent results regarding the presence and lo-
cation of any adenoma. The other 46 patients remained
under strict control, i.e., repeated measurements of the
serum calcium levels and PTH levels at least twice a year
as directed by the ISBD consensus guidelines referred to





users (n = 15)
p value
Gender (% female) 61.5 66.7 0.934
Age (years) 47 (13) 40 (9) 0.036
Creatinine (μmol/l) 77.59 (18.9) 68.45 (14.8) 0.115
TSH (mU/l) 2.7 (3.6) 1.9 (0.7) 0.454
Sodium (mmol/l) 140.5 (2.26) 140.9 (1.30) 0.353
Potassium (mmol/l) 4.5 (0.35) 4.3 (0.26) 0.025
Calcium serum level (mmol/l) 2.49 (0.11) 2.37 (0.10) <0.001
Mean values and standard deviation (SD) between brackets. Statistical
differences were calculated by means of the Pearson’s chi-square test (gender)
and Student’s independent t test (all other variables).not referred for further analysis (Ng et al. 2009). Follow-up
is currently conducted to obtain better insight into the
clinical course of these patients.
Discussion
Main findings
In this cross-sectional study, we found a significant
higher prevalence of hypercalcemia in patients using
lithium compared to that of the control group of pa-
tients without a current and previous history of lithium
treatment (p = 0.001). In addition, the development of
hypercalcemia was correlated to the cumulative time
that lithium was taken regardless whether this was con-
tinuous or with one or more interruptions of various
durations.
Strengths and weaknesses
This study is the first to determine the prevalence of hy-
percalcemia in a major cohort of psychiatric patients.
Our results regarding the prevalence corroborates with
previous studies (Bendz et al. 1996; Ananth and Dubin
1983; Davis et al. 1981; Järhult et al. 2010; Saunders
et al. 2009; Christensson 1976; Hundley et al. 2005;
Awad et al. 2003; Carchman et al. 2008). However, com-
pared to previous studies, in our study, we included a
large number of patients, and selection bias is less likely
because we used a predefined search for patients that
were currently treated in a large, non-academic psychi-
atric outpatient clinic. Patients attending this clinic re-
flect a regular sample of bipolar outpatients of varying
severity and duration of illness. In most other studies,
patients were selected from an endocrine surgery data-
base instead of a psychiatric cohort. As a consequence,
these cohorts included a highly selected subgroup of
lithium-treated patients since the outcome, i.e., hyper-
parathyroidism, was already present.
In our study, patients were identified based upon their
bipolar disorder, and calcium levels were measured as
part of a routine monitoring schedule. In addition, using
an upper limit for serum calcium levels of 2.60 mmol/L
compared to that of the various lower upper limits up-
hold among different hospitals, psychiatric facilities, and
laboratories, it is unlikely that our results overestimate
the prevalence of hypercalcemia. All other factors such
as medical history, use of other medications besides lith-
ium, and possibly previous surgery were taken into ac-
count. None of these showed a significant difference that
could distort our results.
Although our control group of lithium-naïve patients
was very small compared to the group of lithium users
reflecting the widespread use of lithium for bipolar dis-
order in the Netherlands, the range from low to high
calcium levels seems to be higher in lithium users than
that in the control patients. This may be an indication
Figure 1 Distribution curves of serum calcium levels in lithium users (n = 314) and non-lithium users (n = 15). The red line illustrates the
upper limit of the serum calcium level of 2.60 (mmol/L). The two dotted lines are placed upon the mean serum calcium levels of both groups;
the left dotted line corresponds with the non-lithium users, the right dotted line with the lithium users.
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users due to the binding of lithium to the calcium-
sensing receptor of the parathyroid cell. This binding re-
sults in a lower threshold for the secretion of PTH, im-
plicating that the serum calcium is also higher in all
lithium users, and leading to hypercalcemia in approxi-
mately 15%. Our control group was small (n = 15), and
therefore, such conclusions remain preliminary. Nonethe-
less, this cross-sectional study is the first including a con-
trol group of psychiatric patients, in this perspective.Table 2 Subgroup analysis of lithium users with normal serum
hypercalcemia
Lithium users with serum calci
level ≤2.60 (mmol/l) (n = 265)
Gender (% female) 60.4
Age (years) 47 (13)
Lithium recent dosage (mg dd) 960 (270)
Creatinine (μmol/l) 76.82 (17.00)
TSH (mU/l) 2.8 (3.8)
Sodium (mmol/l) 140.5 (2.20)
Potassium (mmol/l) 4.5 (0.34)
Lithium serum level (mmol/l) 0.74 (0.19)
Lithium period (months) 109 (84)
Lifetime dosage quotient 1.03 × 105 (8.3 × 104)
Mean values and standard deviation (SD) between brackets. Statistical differences w
Student’s independent t test (all other variables).Because lithium is the mainstay for the long-term treat-
ment of bipolar disorder, it is difficult to identify a larger
cohort of control patients.
Whether lithium shifts the calcium set point to the
right or that it uncovers a preexisting hyperparathyroid-
ism remains the question. Because of the absence of
PTH measurements, calcium in 24-h urine specimens,
and proper imaging of patients with suspected LIH, we
were unable to investigate this in our sample, which
poses a limitation of our study.calcium levels compared to lithium users with
um Lithium users with serum calcium











1.63 × 105 (1.3 × 105) 0.002
ere calculated by means of the Pearson’s chi-square test (gender) and
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In the absence of an evidence-based consensus on the
optimal surgical approach in lithium-induced hyperpara-
thyroidism, several studies have been published regard-
ing the different treatment options (Bendz et al. 1996;
Järhult et al. 2010; Saunders et al. 2009; Abdullah et al.
1999; Awad et al. 2003; Carchman et al. 2008). Some ad-
vocate removal of all four glands where others apply a
more focused approach. In order to determine the optimal
treatment for LIH, one has to understand its pathophysi-
ology. However, the underlying mechanism by which lith-
ium induces hyperparathyroidism has not been elucidated
yet. Since lithium was thought to induce hyperplastic
changes to all four glands (based on the idea that all glands
are exposed equally) rather than the formation of one or
multiple adenomas, (Abdullah et al. 1999), routine
complete neck exploration was the surgical procedure
of choice for a long time. The overall prevalence of
multiglandular disease, however, has a broad variance
ranging from only 13% to 52% (Järhult et al. 2010;
Abdullah et al. 1999; Awad et al. 2003; Carchman et al.
2008). And therefore, the notion that the remaining
parathyroid glands will render pathological with time
is perhaps premature and lacks sufficient evidence (Järhult
et al. 2010; Saunders et al. 2009). This would support a
more selective approach and more extensive preoperative
imaging as is common nowadays in primary hyperpara-
thyroidism. At this moment, it is too early to advocate a
certain surgical approach since both theories find equal
supports in the literature. Furthermore, when there is re-
luctance to surgery, a relative new class of drugs called
calcimimetics has been shown to lower the serum calcium
level. Even though the results are promising, one must
realize that this is not a definitive therapy (Houweling
et al. 2012; Rothe et al. 2011).
Conclusions
The present study clearly established that the prevalence
of hypercalcemia is significantly higher in patients using
lithium in a major cohort of patients. Furthermore, our
subgroup analysis showed that the total duration of lith-
ium treatment was significantly longer in the hypercalce-
mia group, regardless of any possible interruptions or
discontinuation of lithium treatment.
Our results underscore that it is mandatory to perform
regular monitoring of serum calcium as well as PTH
levels. LIH cannot be diagnosed based upon signs and
symptoms alone, since these are easily misinterpreted in
the context of mood disorders. With the growing aware-
ness of LIH, future research should focus on the best
treatment for this delicate group of patients.
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